The authors reply

Affiliations

¹ Kolling Institute of Medical Research, Renal Research Laboratory, University of Sydney, St. Leonards, Australia. Electronic address: usha.panchapakesan@sydney.edu.au.
² Department of Medicine, University of Sydney, St. Leonards, Australia.

Free article

Comment

Usha Panchapakesan et al. Kidney Int. 2018 Oct.

Free article

. 2018 Oct;94(4):831.

doi: 10.1016/j.kint.2018.07.003.

¹ Kolling Institute of Medical Research, Renal Research Laboratory, University of Sydney, St. Leonards, Australia. Electronic address: usha.panchapakesan@sydney.edu.au.
² Department of Medicine, University of Sydney, St. Leonards, Australia.

No abstract available

Comment on

Drug repurposing in kidney disease.
Panchapakesan U, Pollock C. Panchapakesan U, et al. Kidney Int. 2018 Jul;94(1):40-48. doi: 10.1016/j.kint.2017.12.026. Epub 2018 Apr 6. Kidney Int. 2018. PMID: 29628139 Review.
Xanthine oxidase inhibitors may prevent or slow chronic kidney disease even in the absence of hyperuricemia.
Eleftheriadis T, Pissas G, Liakopoulos V, Stefanidis I. Eleftheriadis T, et al. Kidney Int. 2018 Oct;94(4):830-831. doi: 10.1016/j.kint.2018.06.019. Kidney Int. 2018. PMID: 30243322 No abstract available.